evaluation of the inhibitory effects of bavachinin and bavachin on human monoamine oxidases a and b
Clicks: 103
ID: 173529
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
103 views
15 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #799 of 899 articles by views in ACS applied materials & interfaces
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 899 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Monoamine oxidase B inhibitors (MAO-BIs) are used in the early management of Parkinson’s disease (PD). Long-term suspected side effects of MAO-B classical inhibitors established the need for safer alternative therapeutic agents. In our study, the flavanone bavachinin (BNN) and its analog bavachin (BVN) found in the seeds of Psoralea corylifolia L. ethanolic extract (PCSEE) were investigated for their human MAO-A and MAO-B (hMAO-A and hMAO-B) inhibition. Both PCSEE and BNN effectively reduced hMAO-B activity more than hMAO-A while BVN had activating effects. BNN showed selective hMAO-B inhibition (IC50 ~ 8.82 μM) more than hMAO-A (IC502009;~ 189.28 μM). BNN in the crude extract was determined by HPLC, also validated by TLC showing a yield of 0.21% PCSEE dry weight. BNN competitively inhibited hMAO-A and hMAO-B, with a lower hMAO-B Ki than hMAO-A Ki by 10.33-fold, and reduced hMAO-B Km/Vmax efficiency ratio to be comparable to the standard selegiline. Molecular docking examination of BNN and BVN predicted an indirect role of BNN C7-methoxy group for its higher affinity, selectivity, and reversibility as an MAO-BI. These findings suggest that BNN, which is known to be a potent PPAR-γ agonist, is a selective and competitive hMAO-B inhibitor and could be used in the management of PD.
| Reference Key |
zarmouh2015evidence-basedevaluation
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Najla O. Zarmouh;Elizabeth A. Mazzio;Faisel M. Elshami;Samia S. Messeha;Suresh V. K. Eyunni;Karam F. A. Soliman |
| Journal | ACS applied materials & interfaces |
| Year | 2015 |
| DOI |
10.1155/2015/852194
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.